Omni Partners LLP acquired a new stake in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 147,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,707,000. Paratek Pharmaceuticals makes up about 0.5% of Omni Partners LLP’s holdings, making the stock its 21st largest position. Omni Partners LLP owned 0.53% of Paratek Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PRTK. C WorldWide Group Holding A S lifted its position in shares of Paratek Pharmaceuticals by 449.3% during the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after buying an additional 359,400 shares in the last quarter. Pictet Asset Management Ltd. purchased a new position in Paratek Pharmaceuticals in the 2nd quarter worth approximately $6,957,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Paratek Pharmaceuticals in the 3rd quarter worth approximately $8,598,000. State Street Corp lifted its holdings in Paratek Pharmaceuticals by 112.3% in the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after purchasing an additional 325,856 shares in the last quarter. Finally, Numeric Investors LLC purchased a new position in Paratek Pharmaceuticals in the 2nd quarter worth approximately $6,449,000. 84.30% of the stock is currently owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) opened at $19.65 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53. Paratek Pharmaceuticals, Inc. has a twelve month low of $12.90 and a twelve month high of $29.00.

A number of research analysts recently commented on the company. BidaskClub raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 8th. Robert W. Baird reissued a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Finally, Guggenheim assumed coverage on Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.00.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/147700-shares-in-paratek-pharmaceuticals-inc-prtk-purchased-by-omni-partners-llp/1732272.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.